Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 – 14, 2021. Details for the presentation are as follows:

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

DuPont de Nemours

Albertsons Companies

Agora

Tyson Foods

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.

DuPont De Nemours, Inc Among Today's Trending Stocks

Pfizer

SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in Greater China and other parts of Asia, today announced that Spero Therapeutics, Inc. (Nasdaq: SPRO), a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. (NYSE: PFE) for SPR206, Spero's intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting.  Under the terms of the licensing agreement, Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories.

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

The small biopharma's work has captured the attention of a much bigger player.

Why Spero Therapeutics Stock Is Up 15% Today

The stock price of Spero Therapeutics, Inc. (Nasdaq: SPRO) increased by over 25% pre-market. This is why it happened.

SPRO Stock Price Increases Over 25% Pre-Market: Why It Happened

Spero Therapeutics Inc (NASDAQ: SPRO) announced that Pfizer Inc (NYSE: PFE) would contribute $40 million to the company through its Breakthrough Growth Initiative focusing on advancing patient care. Pfizer acquired around 2.4 million SPRO shares at $16.93 per share.

Spero Therapeutics Stock Surges On $40M Equity Funding, SPR206 Licensing Pact With Pfizer

Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties.

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

American Express

AcelRx Pharmaceuticals

Alexandria Real Estate Equities

Altria

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified American Express Company among others.

American Express Company Ranked Among Today's Trending Stocks

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero's potentiator platform and is being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. These trials, which are now open for enrollment, include a bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment clinical trial.

Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206

The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206 The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206

Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript

Tebipenem HBr remains on track for NDA submission in the second half of 2021

Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m. ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript

Tebipenem HBr advancing towards NDA submission in the second half of 2021

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and full-year 2020 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero's investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.

Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?

CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587, which is directed to a crystalline formulation of tebipenem HBr, Spero's oral carbapenem in development for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is running three clinical phase therapeutic programs including Tebipenem HBr - Phase 3 [complete] for cUTIs, SPR720 - Phase 2a for NMT-PD, and SPR206 - Phase 1 for MDRi.

Spero: Tebipenem HBr's H2 2021 NDA, SPR720's Phase 2a Data Release And More

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Spero Therapeutics Added to the NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero's oral antimicrobial agent in development for the treatment of NTM-PD.

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference taking place December 1 – 3, 2020.

News for Spero Therapeutics Stock (SPRO)